Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Equities research analysts at William Blair cut their Q4 2026 earnings estimates for shares of Duluth in a research report issued to clients and investors on Thursday, March 13th. William Blair ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

Palantir (NASDAQ:PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price ...

Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...

William Blair believes investors could view Viking Therapeutics (VKTX)’ multi-year manufacturing pact with CordenPharma as a negative to ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...